Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to -$40.6 million.

  • Tg Therapeutics' Free Cash Flow fell 89.98% to -$23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.2 million, marking a year-over-year decrease of 149.88%. This contributed to the annual value of -$40.6 million for FY2024, which is 29.12% down from last year.
  • Per Tg Therapeutics' latest filing, its Free Cash Flow stood at -$40.6 million for FY2024, which was down 29.12% from -$31.4 million recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Free Cash Flow peaked at -$31.4 million during FY2023, and registered a low of -$296.0 million during FY2021.
  • For the 3-year period, Tg Therapeutics' Free Cash Flow averaged around -$82.7 million, with its median value being -$40.6 million (2024).
  • In the last 5 years, Tg Therapeutics' Free Cash Flow slumped by 61.63% in 2020 and then spiked by 82.17% in 2023.
  • Yearly analysis of 5 years shows Tg Therapeutics' Free Cash Flow stood at -$214.9 million in 2020, then tumbled by 37.78% to -$296.0 million in 2021, then soared by 40.49% to -$176.2 million in 2022, then surged by 82.17% to -$31.4 million in 2023, then declined by 29.12% to -$40.6 million in 2024.